Selected Grants
Epigenetic Programming of T Cells for Enhanced Cellular Immunotherapy
ResearchCo Investigator · Awarded by National Institutes of Health · 2024 - 2029Role of mregDC-PCSK9-mediated Inhibition of DC Antigen Cross-Presentation in Tumor Immunotherapy Resistance
ResearchCollaborator · Awarded by V Foundation for Cancer Research · 2024 - 2027Novel roles of PCSK9 in regulating the tumor immune microenvironment during radiotherapy
ResearchCo-Principal Investigator · Awarded by National Cancer Institute · 2022 - 2027Duke ACS Institutional Research Grant
ResearchSignificant Contributor · Awarded by American Cancer Society, Inc. · 2024 - 2026Duke Center for Advancement of Child Health (CAtCH).
Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2021 - 2026Epigenetic Engineering of Tumor-Infiltrating Lymphocytes
ResearchCo Investigator · Awarded by Yosemite · 2025 - 2025Investigating the Role of a Novel Dendritic Cell Subset within Sentinel Lymph Node Tissues in Immune Evasion and Melanomagenesis
ResearchCollaborator · Awarded by Department of Defense · 2021 - 2025Anti-PD1 in combination with an inhibitor of PCSK9 to increase MHC class I molecule expression on tumor cells as immunotherapy for NSCLC
Clinical TrialPrincipal Investigator · Awarded by Department of Defense · 2021 - 2025Phase Ib Study of MEM-288 Oncolytic Virus in Combination with Nivolumab in Non-Small Cell Lung Cancer (NSCLC)
ResearchMentor · Awarded by Bristol-Myers Squibb Foundation · 2023 - 2025Clinical Biomarker Study of the Tumor NLRP3 Inflammasome and its Role in Anti-PD-1 Immunotherapy Resistance
ResearchCollaborator · Awarded by Conquer Cancer Foundation · 2021 - 2024Nektar PROPEL
Clinical TrialPrincipal Investigator · Awarded by Nektar Therapeutics · 2020 - 2024Discovering Novel Tumor-Reactive Antibodies in Pembrolizumab-Treated NSCLC
ResearchMentor · Awarded by Lung Cancer Initiative of North Carolina · 2023 - 2023Eco-Evolutionary dynamics of NSCLC to immunotherapy: Response and Resistance
ResearchPrincipal Investigator · Awarded by H. Lee Moffitt Cancer Center & Research Institute · 2019 - 2023Use of an oncolytic adenovirus to promote anti-tumor T-cell responses in ovarian cancer
ResearchMentor · Awarded by Foundation for Women's Cancer · 2022 - 2023T32 UNC - Duke Immunotherapy Training Program
Inst. Training Prgm or CMEPreceptor · Awarded by University of North Carolina - Chapel Hill · 2021 - 2022Evaluating the Impact of PCSK9 on the Composition of the Tumor-Immune Microenvironment and Treatment Response to Immune Checkpoint Blockade in NSCLC
FellowshipCo-Mentor · Awarded by Lung Cancer Initiative of North Carolina · 2021 - 2022Identifying Epigenetic Biomarkers that Predict Response to Immunotherapy in Lung Cancer Patients
ResearchMentor · Awarded by Lung Cancer Initiative of North Carolina · 2020 - 2022Anonymous Donation
ResearchPrincipal Investigator · Awarded by Anonymous Trust · 2020 - 2022Targeting Immunosuppressive Cancer Associated Fibroblasts and Immune Checkpoints in NSCLC
ResearchPrincipal Investigator · Awarded by H. Lee Moffitt Cancer Center & Research Institute · 2019 - 2022Tumor Infiltrating lymphocyte adoptive T cell therapy for NSCLC
ResearchPrincipal Investigator · Awarded by H. Lee Moffitt Cancer Center & Research Institute · 2019 - 2021CA191146: Long-acting PEG-like conjugates of an immune checkpoint inhibitor and a selective cytokine for combination immunotherapy
ResearchCo-Mentor · Awarded by United States Army Medical Research Acquisition Activity · 2020 - 2021A PHASE 1/2, OPEN-LABEL, MULTICENTER STUDY OF THE COMBINATION OF NKTR-214 AND NIVOLUMAB OR THE COMBINATION OF NKTR-214, NIVOLUMAB, AND OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH SELECT LOCALLY ADVANCED OR METASTATIC SOLID TUMOR MALIGNANCIES
Clinical TrialPrincipal Investigator · Awarded by Nektar Therapeutics · 2019 - 2020External Relationships
- Achilles Therapeutics
- Cellepus Therapeutics
- Guardian Bio
- Immutep
- Leap Therapeutics
- Memgen
- RAPT Biotherapeutics
- Shoreline
- Tubulis
- Xilis, Inc
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.